Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings.

Autor: Tanaka N; Department of Urology, Keio University School of Medicine, Tokyo, Japan; Department of Urology, Saitama City Hospital, Saitama, Japan. Electronic address: urotanaka@gmail.com., Mizuno R; Department of Urology, Keio University School of Medicine, Tokyo, Japan. Electronic address: mizunor@z7.keio.jp., Shirotake S; Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan., Ito K; Department of Urology, National Defense Medical College, Tokorozawa, Saitama, Japan., Yasumizu Y; Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan., Masunaga A; Department of Urology, National Defense Medical College, Tokorozawa, Saitama, Japan., Ito Y; Department of Urology, Saiseikai Central Hospital, Tokyo, Japan., Miyazaki Y; Department of Urology, Keio University School of Medicine, Tokyo, Japan., Hagiwara M; Department of Urology, Ichikawa General Hospital, Tokyo Dental College, Ichikawa, Chiba, Japan., Kanao K; Department of Urology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan., Mikami S; Division of Diagnostic Pathology, Keio University Hospital, Tokyo, Japan., Nakagawa K; Department of Urology, Ichikawa General Hospital, Tokyo Dental College, Ichikawa, Chiba, Japan., Momma T; Department of Urology, National Hospital Organization Saitama Hospital, Wako, Saitama, Japan., Masuda T; Department of Urology, Saitama City Hospital, Saitama, Japan., Asano T; Department of Urology, National Defense Medical College, Tokorozawa, Saitama, Japan., Oyama M; Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan., Oya M; Department of Urology, Keio University School of Medicine, Tokyo, Japan.
Jazyk: angličtina
Zdroj: Urologic oncology [Urol Oncol] 2016 Jul; Vol. 34 (7), pp. 293.e17-25. Date of Electronic Publication: 2016 Apr 01.
DOI: 10.1016/j.urolonc.2016.02.023
Abstrakt: Purpose: To investigate the prognostic effect of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model reclassification after targeted therapy administration in metastatic renal cell carcinoma (mRCC).
Patients and Method: A total of 245 mRCC patients treated with targeted therapy are included. The IMDC model reclassification is performed at 1 month after treatment induction of both first-line and second-line targeted therapy.
Results: Of the 245 patients, 74 (30.2%) are divided into different risk groups by the IMDC model reclassification after first-line targeted therapy, and patients newly classified with intermediate risk tend to have better overall survival than those remaining in the primary poor-risk group (P = 0.018). Of the 119 patients treated with subsequent second-line targeted therapy, 25 (21.0%) are divided into different risk groups by the IMDC model reclassification after second-line targeted therapy, and patients newly classified with poor risk tend to have increased all-cause mortality compared with those remaining in the primary intermediate-risk group (P = 0.007), whereas patients newly classified with intermediate risk tend to have better overall survival than those remaining in the primary poor-risk group (P = 0.034).
Conclusion: Approximately a quarter of the mRCC patients are classified into different risk groups of the IMDC model following targeted therapy administration in the first-line and second-line settings. There is a significant difference in overall survival of subgroups after the IMDC model reclassifications.
(Copyright © 2016 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: